Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Accumulated Expenses (2020 - 2026)

BioScience Health Innovations has reported Accumulated Expenses over the past 7 years, most recently at $22781.0 for Q1 2026.

  • Quarterly Accumulated Expenses rose 9.79% to $22781.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $22781.0 through Mar 2026, up 9.79% year-over-year, with the annual reading at $7957.0 for FY2025, 32.77% up from the prior year.
  • Accumulated Expenses was $22781.0 for Q1 2026 at BioScience Health Innovations, up from $7957.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $24500.0 in Q2 2025 and troughed at $450.0 in Q1 2022.
  • The 5-year median for Accumulated Expenses is $4246.5 (2024), against an average of $8117.7.
  • Year-over-year, Accumulated Expenses soared 1125.0% in 2025 and then increased 9.79% in 2026.
  • A 5-year view of Accumulated Expenses shows it stood at $450.0 in 2022, then skyrocketed by 222.22% to $1450.0 in 2023, then soared by 313.31% to $5993.0 in 2024, then skyrocketed by 32.77% to $7957.0 in 2025, then soared by 186.3% to $22781.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Accumulated Expenses are $22781.0 (Q1 2026), $7957.0 (Q4 2025), and $6686.0 (Q3 2025).